PriceTargets.com logo

CV Sciences - CVSI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.04 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CVSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CV Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVSI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for CV Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.04.

This chart shows the closing price for CVSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in CV Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/6/2022Roth CapitalReiterated RatingNeutral
12/10/2021Cantor FitzgeraldLower TargetNeutral$0.42 ➝ $0.17
3/25/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$0.50
3/19/2021Roth CapitalLower TargetNeutral$0.75 ➝ $0.60
3/19/2021Piper SandlerDowngradeOverweight ➝ Neutral$0.50
1/29/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$1.35 ➝ $0.65
12/8/2020Cantor FitzgeraldReiterated RatingOverweight
8/7/2020Northland SecuritiesReiterated RatingBuy$0.95
6/12/2020CowenInitiated CoverageMarket Perform$0.75
4/7/2020Cantor FitzgeraldBoost TargetOverweight$0.80 ➝ $1.70
3/17/2020Roth CapitalDowngradeBuy ➝ Neutral
3/9/2020Cantor FitzgeraldBoost TargetOverweight$1.60 ➝ $4.20
11/7/2019Cantor FitzgeraldInitiated CoverageOverweight
8/12/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$5.00
5/16/2019Roth CapitalInitiated CoverageBuy ➝ Buy$9.00
5/9/2019Northland SecuritiesReiterated RatingBuy
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CV Sciences logo
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Read More

Today's Range

Now: $0.04
Low: $0.04
High: $0.04

50 Day Range

MA: $0.04
Low: $0.03
High: $0.04

52 Week Range

Now: $0.04
Low: $0.03
High: $0.06

Volume

92,028 shs

Average Volume

225,896 shs

Market Capitalization

$6.53 million

P/E Ratio

2.00

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of CV Sciences?

The following Wall Street sell-side analysts have issued stock ratings on CV Sciences in the last year:
View the latest analyst ratings for CVSI.

What is the current price target for CV Sciences?

0 Wall Street analysts have set twelve-month price targets for CV Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CV Sciences in the next year.
View the latest price targets for CVSI.

What is the current consensus analyst rating for CV Sciences?

CV Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CVSI.

What other companies compete with CV Sciences?

Other companies that are similar to CV Sciences include Ainos, Vaccinex, First Wave BioPharma, Kazia Therapeutics and Avenue Therapeutics. Learn More about companies similar to CV Sciences.

How do I contact CV Sciences' investor relations team?

CV Sciences' physical mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company's listed phone number is (866) 290-2157 and its investor relations email address is [email protected]. The official website for CV Sciences is www.cvsciences.com. Learn More about contacing CV Sciences investor relations.